Page 42 - அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results March 04, 2021 16:42 ET | Source: Cellectis Inc. Cellectis Inc. New York, New York, UNITED STATES Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers Preliminary results from our Phase 1 BALLI-01 clinical study of UCART22 in adults with r/r B-ALL presented in oral session at 2020 ASH Annual Meeting Partner Allogene Therapeutics presented initial results from Phase 1 ALPHA clinical study of licensed ALLO-501 in r/r NHL at 2020 ASCO Annual Meeting and from Phase 1 UNIVERSAL clinical study of licensed ALLO-715 in r/r MM at 2020 ASH Annual Meeting

United statesNew yorkFrance generalNorth carolinaStanford universityStephan gruppLaurent poirotPhilippe duchateauCytovia theraputicsKyung nam wortmanSteve doaresIovance biotherapeuticsSimon harnestMark frattiniLeopold berteaIovance biotherapeutic